Thank you, and good morning, everyone. Expenses of $24 billion were up 5% year on year, predominantly driven by higher volume and revenue-related expenses and compensation growth, including from ...
Travere Therapeutics FY25 sales surged on Filspari, but the FDA FSGS label decision was delayed to April. Click here to read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback